Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
OMED's Cash to Debt is ranked higher than
79% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. OMED: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OMED' s 10-Year Cash to Debt Range
Min: 326.31   Max: No Debt
Current: No Debt

Equity to Asset 0.29
OMED's Equity to Asset is ranked higher than
51% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.24 vs. OMED: 0.29 )
Ranked among companies with meaningful Equity to Asset only.
OMED' s 10-Year Equity to Asset Range
Min: -2.45   Max: 0.7
Current: 0.29

-2.45
0.7
Interest Coverage No Debt
OMED's Interest Coverage is ranked higher than
79% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OMED: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OMED' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 1.50
M-Score: 265.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -118.56
OMED's Operating margin (%) is ranked higher than
66% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -1702.36 vs. OMED: -118.56 )
Ranked among companies with meaningful Operating margin (%) only.
OMED' s 10-Year Operating margin (%) Range
Min: -161.06   Max: -48.52
Current: -118.56

-161.06
-48.52
Net-margin (%) -117.20
OMED's Net-margin (%) is ranked higher than
65% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -1412.53 vs. OMED: -117.20 )
Ranked among companies with meaningful Net-margin (%) only.
OMED' s 10-Year Net-margin (%) Range
Min: -152.47   Max: -47.87
Current: -117.2

-152.47
-47.87
ROE (%) -59.02
OMED's ROE (%) is ranked higher than
51% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -61.96 vs. OMED: -59.02 )
Ranked among companies with meaningful ROE (%) only.
OMED' s 10-Year ROE (%) Range
Min: -51.43   Max: -51.43
Current: -59.02

ROA (%) -19.02
OMED's ROA (%) is ranked higher than
63% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -39.06 vs. OMED: -19.02 )
Ranked among companies with meaningful ROA (%) only.
OMED' s 10-Year ROA (%) Range
Min: -28.05   Max: -12.61
Current: -19.02

-28.05
-12.61
ROC (Joel Greenblatt) (%) -1012.26
OMED's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -1309.62 vs. OMED: -1012.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OMED' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1038.97   Max: -385.14
Current: -1012.26

-1038.97
-385.14
» OMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

OMED Guru Trades in Q2 2014

Jim Simons 59,200 sh (New)
PRIMECAP Management 266,400 sh (-21.81%)
» More
Q3 2014

OMED Guru Trades in Q3 2014

PRIMECAP Management 218,400 sh (-18.02%)
Jim Simons 40,110 sh (-32.25%)
» More
Q4 2014

OMED Guru Trades in Q4 2014

PRIMECAP Management 218,400 sh (unchged)
Jim Simons 20,675 sh (-48.45%)
» More
Q1 2015

OMED Guru Trades in Q1 2015

Jim Simons Sold Out
PRIMECAP Management 206,293 sh (-5.54%)
» More
» Details

Insider Trades

Latest Guru Trades with OMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.80
OMED's P/B is ranked lower than
82% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OMED: 10.80 )
Ranked among companies with meaningful P/B only.
OMED' s 10-Year P/B Range
Min: 3.52   Max: 12.85
Current: 10.8

3.52
12.85
P/S 16.00
OMED's P/S is ranked lower than
53% of the 1065 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OMED: 16.00 )
Ranked among companies with meaningful P/S only.
OMED' s 10-Year P/S Range
Min: 1.03   Max: 20.34
Current: 16

1.03
20.34
Current Ratio 6.43
OMED's Current Ratio is ranked higher than
70% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 2.70 vs. OMED: 6.43 )
Ranked among companies with meaningful Current Ratio only.
OMED' s 10-Year Current Ratio Range
Min: 1.89   Max: 6.43
Current: 6.43

1.89
6.43
Quick Ratio 6.43
OMED's Quick Ratio is ranked higher than
72% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. OMED: 6.43 )
Ranked among companies with meaningful Quick Ratio only.
OMED' s 10-Year Quick Ratio Range
Min: 1.89   Max: 6.43
Current: 6.43

1.89
6.43
Days Sales Outstanding 60.09
OMED's Days Sales Outstanding is ranked higher than
75% of the 1065 Companies
in the Global Biotechnology industry.

( Industry Median: 365.00 vs. OMED: 60.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMED' s 10-Year Days Sales Outstanding Range
Min: 0.22   Max: 65.72
Current: 60.09

0.22
65.72

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.90
OMED's Price/Net Cash is ranked higher than
59% of the 1061 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OMED: 13.90 )
Ranked among companies with meaningful Price/Net Cash only.
OMED' s 10-Year Price/Net Cash Range
Min: 5.05   Max: 15.62
Current: 13.9

5.05
15.62
Price/Net Current Asset Value 12.60
OMED's Price/Net Current Asset Value is ranked higher than
59% of the 1061 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OMED: 12.60 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OMED' s 10-Year Price/Net Current Asset Value Range
Min: 4.42   Max: 13.29
Current: 12.6

4.42
13.29
Price/Tangible Book 10.50
OMED's Price/Tangible Book is ranked lower than
64% of the 1039 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OMED: 10.50 )
Ranked among companies with meaningful Price/Tangible Book only.
OMED' s 10-Year Price/Tangible Book Range
Min: 4.22   Max: 9.37
Current: 10.5

4.22
9.37
Price/Median PS Value 1.40
OMED's Price/Median PS Value is ranked higher than
62% of the 1065 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. OMED: 1.40 )
Ranked among companies with meaningful Price/Median PS Value only.
OMED' s 10-Year Price/Median PS Value Range
Min: 0.11   Max: 1.58
Current: 1.4

0.11
1.58
Earnings Yield (Greenblatt) -10.50
OMED's Earnings Yield (Greenblatt) is ranked lower than
59% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OMED: -10.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
OMED' s 10-Year Earnings Yield (Greenblatt) Range
Min: -11.9   Max: 0
Current: -10.5

-11.9
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:O0M.Germany,
OncoMed Pharmaceuticals Inc was originally incorporated in July 19, 2004 in Delaware. The Company is a clinical development-stage biopharmaceutical company focused on discovering and developing novel protein therapeutics targeting cancer stem cells, or CSCs. CSCs, also known as tumor-initiating cells, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs exhibit certain properties which include the capacity to divide and give rise to new CSCs via self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. It faces competition from many pharmaceutical and biotechnology companies that are also researching and selling products designed to address these markets. The Company has a total of over 400 patents and pending patent applications in our patent portfolio. The Company's product candidates are subject to regulation by the FDA as biologics.
» More Articles for OMED

Headlines

Articles On GuruFocus.com
Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 

More From Other Websites
Celgene's 3 Most Important Collaborations May 26 2015
ONCOMED PHARMACEUTICALS INC Financials May 15 2015
OncoMed to Present at UBS Global Healthcare Conference May 14 2015
OncoMed to Present at UBS Global Healthcare Conference May 14 2015
OncoMed reports 1Q loss May 07 2015
OncoMed reports 1Q loss May 07 2015
OncoMed Pharmaceuticals Announces First Quarter 2015 Financial Results May 07 2015
OncoMed Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today May 07 2015
ONCOMED PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2015
OncoMed Pharmaceuticals Announces First Quarter 2015 Financial Results May 07 2015
Q1 2015 OncoMed Pharmaceuticals Inc Earnings Release - After Market Close May 07 2015
OncoMed Pharmaceuticals to Report First Quarter 2015 Financial Results on Thursday, May 7, 2015 May 04 2015
OncoMed to Present at the Credit Suisse Antibody Day May 04 2015
OncoMed to Present at the Credit Suisse Antibody Day May 04 2015
OncoMed Pharmaceuticals to Report First Quarter 2015 Financial Results on Thursday, May 7, 2015 May 04 2015
OncoMed Publishes Data on Tarextumab's Anti-Cancer Stem Cell Activity in Clinical Cancer Research May 01 2015
OncoMed Publishes Data on Tarextumab's Anti-Cancer Stem Cell Activity in Clinical Cancer Research May 01 2015
OncoMed Highlights Immuno-Oncology Discoveries During 2015 Research & Development Day Apr 29 2015
OncoMed Highlights Immuno-Oncology Discoveries During 2015 Research & Development Day Apr 29 2015
ONCOMED PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Apr 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK